MXPA04008303A - Inhibidores de la farnesil proteina transferasa como agentes antitumorales. - Google Patents

Inhibidores de la farnesil proteina transferasa como agentes antitumorales.

Info

Publication number
MXPA04008303A
MXPA04008303A MXPA04008303A MXPA04008303A MXPA04008303A MX PA04008303 A MXPA04008303 A MX PA04008303A MX PA04008303 A MXPA04008303 A MX PA04008303A MX PA04008303 A MXPA04008303 A MX PA04008303A MX PA04008303 A MXPA04008303 A MX PA04008303A
Authority
MX
Mexico
Prior art keywords
protein transferase
farnesyl protein
antitumor agents
transferase inhibitors
compounds
Prior art date
Application number
MXPA04008303A
Other languages
English (en)
Spanish (es)
Inventor
Ray A James
Original Assignee
Pharmacopeia Drug Discovery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Pharmacopeia Drug Discovery filed Critical Pharmacopeia Drug Discovery
Publication of MXPA04008303A publication Critical patent/MXPA04008303A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/06Ring systems of three rings
    • C07D221/16Ring systems of three rings containing carbocyclic rings other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MXPA04008303A 2002-02-27 2003-02-25 Inhibidores de la farnesil proteina transferasa como agentes antitumorales. MXPA04008303A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents
PCT/US2003/005479 WO2003072549A1 (en) 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents

Publications (1)

Publication Number Publication Date
MXPA04008303A true MXPA04008303A (es) 2005-11-23

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04008303A MXPA04008303A (es) 2002-02-27 2003-02-25 Inhibidores de la farnesil proteina transferasa como agentes antitumorales.

Country Status (19)

Country Link
US (1) US7342016B2 (https=)
EP (1) EP1492772A1 (https=)
JP (1) JP2005525356A (https=)
KR (1) KR20040098004A (https=)
CN (1) CN100537542C (https=)
AR (1) AR039557A1 (https=)
AU (1) AU2003215389B2 (https=)
BR (1) BR0308071A (https=)
CA (1) CA2477328A1 (https=)
CO (1) CO5611194A2 (https=)
IL (1) IL163673A0 (https=)
MX (1) MXPA04008303A (https=)
NO (1) NO20044053L (https=)
NZ (1) NZ534809A (https=)
PE (1) PE20031038A1 (https=)
PL (1) PL372335A1 (https=)
RU (1) RU2004128465A (https=)
TW (1) TW200303867A (https=)
WO (1) WO2003072549A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA101945C2 (uk) * 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
EP1660477B1 (en) * 2003-08-07 2008-12-10 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents
KR20070034524A (ko) * 2004-05-28 2007-03-28 버텍스 파마슈티칼스 인코포레이티드 무스카린 수용체 조정자
KR20070034049A (ko) 2004-06-09 2007-03-27 글락소 그룹 리미티드 피롤로피리딘 유도체
EP1833481A1 (en) 2004-12-14 2007-09-19 Schering Corporation Farnesyl protein transferase inhibitors and methods for treating proliferative diseases
CN101124219A (zh) * 2004-12-21 2008-02-13 先灵公司 用作抗肿瘤剂的新的法呢基蛋白质转移酶抑制剂
JP2009523799A (ja) * 2006-01-19 2009-06-25 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビターとしてのピペラジン誘導体
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
HUE029445T2 (en) * 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
CA2730190A1 (en) 2008-07-14 2010-01-21 Queen's University At Kingston Pharmaceutical compositions comprising ret inhibitors and methods for the treatment of cancer
EP2408449A4 (en) 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
CN115385892A (zh) * 2021-10-28 2022-11-25 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5393890A (en) * 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
US5416087A (en) * 1990-10-10 1995-05-16 Wong; Jesse K. Bis-benzo, cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
IL125062A (en) * 1995-12-22 2003-11-23 Schering Corp Tricyclic amides and pharmaceutical compositions containing them for inhibition of g-protein function and for treatment of proliferative diseases
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
CN1237176A (zh) * 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU8253698A (en) 1997-06-17 1999-01-04 Schering Corporation Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
ZA985205B (en) 1997-06-17 1998-12-15 Schering Corp Novel n-substituted urea inhibitors of arnesyl-protein transferase
CN1266433A (zh) 1997-06-17 2000-09-13 先灵公司 用于抑制法呢基蛋白转移酶的苯并吡啶并环庚烷化合物
IL133449A0 (en) 1997-06-17 2001-04-30 Schering Corp Benzo (5, 6) cyclohepta (1, 2-b) pyridine derivatives as farnesyl protein transferase inhibitors
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
TR200101754T2 (tr) 1998-12-18 2002-05-21 Schering Corporation Farnezil protein transferaz inhibitörleri
HUP0202152A2 (en) 1998-12-18 2002-10-28 Schering Corp Tricyclyc farnesyl protein transferase inhibitors
WO2001045740A2 (en) * 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
JP5491681B2 (ja) 2000-02-04 2014-05-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 乳ガンの治療のためのファルネシルタンパク質トランスフェラーゼ阻害剤
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
CA2468996A1 (en) * 2001-12-03 2003-06-12 Schering Corporation Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer
EP1660477B1 (en) * 2003-08-07 2008-12-10 Schering Corporation Novel farnesyl protein transferase inhibitors as antitumor agents

Also Published As

Publication number Publication date
EP1492772A1 (en) 2005-01-05
BR0308071A (pt) 2004-12-21
AU2003215389B2 (en) 2007-10-18
NO20044053L (no) 2004-11-26
KR20040098004A (ko) 2004-11-18
TW200303867A (en) 2003-09-16
JP2005525356A (ja) 2005-08-25
IL163673A0 (en) 2005-12-18
RU2004128465A (ru) 2005-09-27
CA2477328A1 (en) 2003-09-04
NZ534809A (en) 2007-12-21
US7342016B2 (en) 2008-03-11
US20040122018A1 (en) 2004-06-24
AU2003215389A1 (en) 2003-09-09
WO2003072549A1 (en) 2003-09-04
CN100537542C (zh) 2009-09-09
PE20031038A1 (es) 2004-01-10
CO5611194A2 (es) 2006-02-28
CN1630641A (zh) 2005-06-22
AR039557A1 (es) 2005-02-23
PL372335A1 (en) 2005-07-11

Similar Documents

Publication Publication Date Title
MXPA04008303A (es) Inhibidores de la farnesil proteina transferasa como agentes antitumorales.
PL1635835T3 (pl) Pochodne 2-aminopirymidyny jako inhibitory kinazy RAF
MY141457A (en) 4-mercaptopyrrolidine derivates a farnesyl transferase inhibitors
MXPA05009985A (es) Ligandos de receptores de canabinoides.
MY162174A (en) Azetidines mek inhibitors for the treatment of proliferative diseases
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PL367682A1 (en) Dolastatin 10 derivatives
TW200613243A (en) Novel compounds
PT1678166E (pt) Inibidores de proteína-quinase
MXPA05007352A (es) Compuestos triciclicos inhibidores de proteina quinasa para mejorar la eficacia de agentes antineoplasicos y terapia de radiacion.
GB0112348D0 (en) Compounds
TWI268280B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
SE0302192D0 (sv) Novel compounds
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
DK1056704T3 (da) Antitumormidler
IL151200A0 (en) Tricyclic imidazopyridine prodrug derivatives and pharmaceutical compositions containing the same
EP1453506A4 (en) Topoisomerase GIFT FUNDS
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
MY138124A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
TW200730177A (en) 4 anilino-3-quinolinecarbonitriles for the treatment of cancer
ECSP045249A (es) "inhibidores novedosos de la farnesil proteina transferasa como agentes antitumorales"
NO20061077L (no) Nye farnesyl-protein-transferaseinbibitorer som antitumormidler
DK1551850T3 (da) 2"-oxo-voruscharin og derivater deraf